Journal of Hepatology
Volume 52, Issue 5 , Pages 627-629 , May 2010

Re-emerging interest in hepatitis delta: New insights into the dynamic interplay between HBV and HDV

Received 30 January 2010 ,Accepted 1 February 2010.

References 

  1. Rizzetto M. Hepatitis D: thirty years after. J Hepatol. 2009;50:1043–1050
  2. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31–40
  3. Farci P. Delta hepatitis: an update. J Hepatol. 2003;39:S212–S219
  4. Degertekin H, Yalcin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008;28:494–498
  5. Le Gal F, Marcellin P, Deny P. Reply to “Wedemeyer et al., Hepatitis D – Not a vanishing disease”. Hepatology. 2007;45:1332–1333
  6. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection – not a vanishing disease in Europe!. Hepatology. 2007;45:1331–1332
  7. Erhardt A, Knuth R, Sagir A, Kirschberg O, Heintges T, Haussinger D. Socioepidemiological data on hepatitis delta in a German university clinic–increase in patients from Eastern Europe and the former Soviet Union. Z Gastroenterol. 2003;41:523–526
  8. Gaeta GB, Stroffolini T, Smedile A, Niro G, Mele A. Hepatitis delta in Europe: vanishing or refreshing?. Hepatology. 2007;46:1312–1313
  9. Mele A, Mariano A, Tosti ME, Stroffolini T, Pizzuti R, Gallo G, et al. Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis. 2007;44:e17–e24
  10. Sagnelli E, Stroffolini T, Mele A, Imparato M, Almasio PL. Chronic hepatitis B in Italy: new features of an old disease – approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection. Clin Infect Dis. 2008;46:110–113
  11. Cross TJ, Rizzi P, Horner M, Jolly A, Hussain MJ, Smith HM, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol. 2008;80:277–282
  12. Parana R, Kay A, Molinet F, Viana S, Silva LK, Salcedo JM, et al. HDV genotypes in the Western Brazilian Amazon region: a preliminary report. Am J Trop Med Hyg. 2006;75:475–479
  13. Dimitrakakis M, Gust I. HDV infection in the Western Pacific region. Prog Clin Biol Res. 1991;364:89–96
  14. Romeo R, Del NE, Rumi M, Russo A, Sangiovanni A, de FR, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136:1629–1638
  15. Calle Serrano B, Heidrich B, Jaroszewicz J, Deterding K, Raupach R, Cornberg M, et al. Long-term outcome of hepatitis delta: a 14-year single center experience. Hepatology. 2009;50:A773–A774
  16. Jardi R, Rodriguez F, Buti M, Costa X, Cotrina M, Galimany R, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001;34:404–410
  17. Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology. 2000;32:1106–1110
  18. Heidrich B, Deterding K, Tillmann HL, Raupach R, Manns MP, Wedemeyer H. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat. 2009;16:883–894
  19. Schaper M, Rodriguez-Frias F, Jardi R, Tabernero D, Homs M, Ruiz G, et al. Quantitative longitudinal evaluation of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic complex replicative profile in chronic hepatitis B and D. J Hepatol. 2010;52:658–664
  20. Le GF, Gordien E, Affolabi D, Hanslik T, Alloui C, Deny P, et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol. 2005;43:2363–2369
  21. Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int. 2009;15
  22. Erhardt A, Gerlich W, Starke C, Wend U, Donner A, Sagir A, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int. 2006;26:805–810
  23. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44:728–735
  24. Yurdaydin C, Bozkaya H, Onder FO, Senturk H, Karaaslan H, Akdogan M, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine+interferon vs interferon. J Viral Hepat. 2008;15:314–321
  25. Radjef N, Gordien E, Ivaniushina V, Gault E, Anais P, Drugan T, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol. 2004;78:2537–2544
  26. Makuwa M, Caron M, Souquiere S, Malonga-Mouelet G, Mahe A, Kazanji M. Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa. J Clin Microbiol. 2008;46:754–756
  27. Williams V, Brichler S, Radjef N, Lebon P, Goffard A, Hober D, et al. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol. 2009;90:2759–2767
  28. Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2006;43:100–107
  29. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, et al. Hepatitis B surface antigen levels in the natural history of hepatitis B virus infection: an European perspective. J Hepatol. 2010;52:514–522
  30. Sheldon J, Ramos B, Toro C, Rios P, Martinez-Alarcon J, Bottecchia M, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV–HBV–HDV-coinfected patients?. Antivir Ther. 2008;13:97–102
  31. Shih HH, Jeng KS, Syu WJ, Huang YH, Su CW, Peng WL, et al. Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis D virus. J Virol. 2008;82:2250–2264
  32. Thompson A, Locarnini S, Visvanathan K. The natural history and the staging of chronic hepatitis B: time for reevaluation of the virus–host relationship based on molecular virology and immunopathogenesis considerations?. Gastroenterology. 2007;133:1031–1035
  33. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat. 2005;12:2–9
  34. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–42.
  35. Vietheer PT, Netter HJ, Sozzi T, Bartholomeusz A. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion. J Virol. 2005;79:6570–6573
  36. Blanchet M, Sureau C. Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity. J Virol. 2006;80:11935–11945

PII: S0168-8278(10)00037-1

doi: 10.1016/j.jhep.2010.02.001

Journal of Hepatology
Volume 52, Issue 5 , Pages 627-629 , May 2010

Article Tools

* Image Usage & Resolution